NewsRoom Articles - Page 56 of 230

WednesdayMay 01, 2024 10:00 am

Vitamin D Could Balance Gut Microbiota, Boost Cancer Immunotherapy

Vitamin D plays different roles and is easily available through the sun, meat and plants. Despite this, many individuals are vitamin D deficient. Different studies have looked into the use of vitamin D for the prevention and treatment of different cancers, including bowel, breast, skin and prostate cancer. Prior studies have linked high levels of vitamin D to decreased cancer mortality rate and reduced risk of developing cancer. In addition, researchers have explored vitamin D use in conjunction with immunotherapy. This type of treatment uses the patient’s immune system to improve its ability to eliminate cancer cells. Immunotherapy treatments include…

WednesdayMay 01, 2024 9:45 am

PaxMedica Inc. (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDA

PaxMedica has completed its three registration/validation batches of PAX-101, an IV formulation of suramin The completed batches are a significant step toward submitting a New Drug Application to the U.S. Food and Drug Administration in the fourth quarter of 2024 PaxMedica aims to establish a sustainable global supply chain for PAX-101 and to advance research and clinical trials targeting Autism Spectrum Disorder (“ASD”), demonstrating a steadfast commitment to addressing complex neurological conditions The ASD treatment market size was valued at $6.94 billion in 2022 and is projected to grow to $13.14 billion by 2030 PaxMedica (NASDAQ: PXMD), a biopharmaceutical company…

WednesdayMay 01, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Presents Findings on Phase 2 VISIONARY-MS LTE at American Academy of Neurology Annual Meeting

Long-term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 exhibited significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p < 0.05) Significantly enhanced clinical outcomes were associated with long-term daily oral CNM-Au8(R) 30 mg treatment (change from original baseline; p < 0.05) Long-term administration of CNM-Au8, spanning up to three years, was well-tolerated, with no significant safety concerns identified This marks the first Phase 2 clinical trial in MS utilizing a non-immunomodulatory drug to achieve a clinical outcome demonstrating improved function supporting remyelination and reparative effects Clene (NASDAQ: CLNN), along with its…

MondayApr 29, 2024 11:15 am

Astiva Health Inc. Innovative Holistic Approach Underscores Understanding That Effective Primary Care Is Foundational

PCPs play pivotal role in successful healthcare approach Evidence shows that primary care helps prevent illness and death Astiva Health has established a healthcare ecosystem where best PCPs are rewarded for expertise, commitment The importance of primary care in a successful healthcare approach has been clearly shown through decades of research. Astiva Health is dedicated to enhancing the quality of medical care through a strong doctor-patient relationship with the success of its model hinging on knowledgeable, competent, and hard-working primary care physicians (“PCPs”) who play a pivotal role in the healthcare system. “Evidence of the health-promoting influence of primary care has been…

MondayApr 29, 2024 10:00 am

Buyers Demand AI-Supported Tools While Exploring Novel eCommerce Categories

As online marketplaces such as Amazon, eBay and myriad other alternatives have become one of the most common ways for consumers to buy goods, these companies have become increasingly demanding on AI-supported tools designed to help them explore novel shopping categories. Consumers now want the same kind of personalized, expert guidance they would get in a brick-and-mortar store when they try out unfamiliar products on online marketplaces, one industry executive says. Artificial intelligence (AI) could fill this role quite effectively by helping online shoppers overcome the initial hesitance involved with trying out new products. Emily Heintz, founder and chief curator…

MondayApr 29, 2024 9:00 am

HealthLynked Corp. (HLYK) Is ‘One to Watch’

HealthLynked Corp. is a pioneering healthcare technology company revolutionizing patient care through innovative digital solutions Dr. Michael T. Dent, CEO and Chairman, leads the company with a significant history of successful healthcare management and technology development; his prior leadership at NeoGenomics Laboratories, a company with a current market cap of approximately $2 billion, underscores his ability to scale healthcare solutions in competitive markets HealthLynked’s recently launched HealthLynked Network is a state-of-the-art, cloud-based platform designed to significantly improve the efficiency and quality of patient care by enabling a seamless exchange of medical information The leadership’s deep involvement and commitment are reflected…

FridayApr 26, 2024 10:00 am

Researchers Seek to Develop Genetically Engineered Brain Cancer Treatment

Scientists at Purdue University are trying to develop a new treatment for glioblastoma tumors. Glioblastoma is a type of cancer that originates in the spinal cord and/or brain. This cancer is fatal, with a median time of survival of 14 months. Conventional treatments for other cancers, including immunotherapy and chemotherapy, are ineffective on this particular cancer. These treatments work by blood cells being taken from a patient then reintroduced back into their bodies after genetic engineering to fight cancer cells. This study was led by associate professor Sandro Matosevic of Purdue’s department of industrial and molecular pharmaceutics. The study’s objective…

WednesdayApr 24, 2024 12:00 pm

“Urgent Action: PaxMedica Inc. (NASDAQ: PXMD) Addresses Medical Crisis in Malawi”

In recent developments, PaxMedica (NASDAQ: PXMD), a renowned biopharmaceutical company specializing in treatments for neurological disorders, has taken swift action to address a pressing medical situation unfolding in Malawi, East Africa. The Ministry of Health (“MOH”) of Malawi has issued a plea for access to IV suramin, a vital medication in combating the life-threatening sleeping sickness crisis affecting the region. PaxMedica swiftly responded to this call for help by committing to provide emergency access to its recently completed registration batches of PAX-101, an IV form of suramin. This decision underscores PaxMedica's dedication to mitigating the devastating impact of sleeping sickness…

WednesdayApr 24, 2024 10:00 am

Advancements in Medical AI Are Improving Timely Esophageal Cancer Detection

Scientists in China recently identified an innovative system that considerably increases the rate of detection of esophageal cancer lesions. Esophageal cancer starts from the esophagus, which ferries food from the throat to the stomach. Early detection of this particular cancer is crucial as rates of survival considerably increase when the illness is identified and treated in its early stages. Unfortunately, this cancer is often diagnosed in its later stages when patients begin presenting with symptoms, which makes treatment more difficult. So, how does artificial intelligence improve esophageal cancer detection? Artificial intelligence analyzes endoscopic images using advanced algorithms to identify lesions…

TuesdayApr 23, 2024 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Advances Abuse Deterrent Tech Addressing Fentanyl Epidemic

Fentanyl is a potent opioid that is associated with a significant risk of abuse and overdose, contributing to a major drug crisis in the United States Fentanyl has legitimate medical uses in managing severe and chronic pain in medical settings such as hospitals and surgical procedures NTRB is advancing its AVERSA(TM) technology that incorporates aversive agents to prevent abuse, diversion, misuse, and accidental exposure to opioids and other drugs with abuse potential NTRB was recently granted a patent for AVERSA(TM), strengthening its intellectual property portfolio in the United States and globally across 45 countries Fentanyl, a potent opioid, poses a…